Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Fusi

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
International Journal of Cancer|October 10, 2009
Long term presence of a single predominant tyrosinase-specific T-cell clone associated with disease control in a patient with metastatic melanomaSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Journal of Translational Medicine|July 3, 2008
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populationsSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2011
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patientsSebastian Ochsenreither, Alberto Fusi, Anne Geikowski, et al.
Journal of Translational Medicine|April 14, 2010
Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patientsSebastian Ochsenreither, Alberto Fusi, Susanne Wojtke, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
"Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrowSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Clinical & Experimental Metastasis|March 23, 2013
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?Antonia Busse, Anne Letsch, Alberto Fusi, et al.
Tumori|July 5, 2003
Current treatments of neuroendocrine tumors role of biotherapy and chemotherapySilvia Della Torre, Giuseppe Procopio, Alberto Fusi, et al.
Molecular and Clinical Oncology|October 2, 2020
Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapyEve Merry, Maria Marples, Sarah Danson, et al.
Tumori|May 11, 2006
Neuroendocrine tumors of the larynx: a clinical report and literature reviewGiuseppe Procopio, Riccardo Ricotta, Alberto Fusi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cellsAntonia Busse, AnneMarie Asemissen, Anika Nonnenmacher, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|October 10, 2009
Long term presence of a single predominant tyrosinase-specific T-cell clone associated with disease control in a patient with metastatic melanomaSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Journal of Translational Medicine|July 3, 2008
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populationsSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2011
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patientsSebastian Ochsenreither, Alberto Fusi, Anne Geikowski, et al.
Journal of Translational Medicine|April 14, 2010
Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patientsSebastian Ochsenreither, Alberto Fusi, Susanne Wojtke, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
"Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrowSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.
Clinical & Experimental Metastasis|March 23, 2013
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?Antonia Busse, Anne Letsch, Alberto Fusi, et al.
Tumori|July 5, 2003
Current treatments of neuroendocrine tumors role of biotherapy and chemotherapySilvia Della Torre, Giuseppe Procopio, Alberto Fusi, et al.
Molecular and Clinical Oncology|October 2, 2020
Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapyEve Merry, Maria Marples, Sarah Danson, et al.
Tumori|May 11, 2006
Neuroendocrine tumors of the larynx: a clinical report and literature reviewGiuseppe Procopio, Riccardo Ricotta, Alberto Fusi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cellsAntonia Busse, AnneMarie Asemissen, Anika Nonnenmacher, et al.
Pageof 5